In vivo erythroid recovery following paclitaxel injury: Correlation between GATA-1, c-MYB, NF-E2, Epo receptor expressions, and apoptosis

Toxicology and Applied Pharmacology

Volumn 194, Issue 3, 2004, Pages 230-238

  Romero Benitez, M M ^a   Aguirre, M V ^a   Juaristi, J A ^a   Alvarez, M A ^a   Trifaro J M ^b   Brandan, N C ^a  

^a UNIVERSIDAD NACIONAL DEL NORDESTE   (Argentina)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Apoptosis; Bcl xL; c MYB; Epo R; GATA 1; NF E2; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ERYTHROID SPECIFIC DNA BINDING FACTOR; ERYTHROID-SPECIFIC DNA-BINDING FACTOR; ERYTHROPOIETIN RECEPTOR; PACLITAXEL; PROTEIN BCL XL; PROTEIN C MYB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 1; TRANSCRIPTION FACTOR NF E2; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOSYNTHESIS; BONE MARROW CELL; BURST FORMING UNIT E; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG EFFECT; ERYTHROID CELL; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FEMALE; GENE EXPRESSION; GENETICS; IMAGE PROCESSING; IMMUNOBLOTTING; IN VIVO STUDY; KINETICS; MACROPHAGE; METABOLISM; MOUSE; NICK END LABELING; NONHUMAN; ONCOGENE MYB; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; STEM CELL;

MURINAE; TRIXIS;

EID: 0842264744     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2003.09.009     Document Type: Article

References (56)

1. Aguirre M., Juaristi J., Alvarez M., Carmuega R., Brandan N. Estudios in vitro e in vivo de la recuperación eritropoyética murina post-tratamiento con ciclofosfamida. Sangre. 44:1999;182-187.
2. Andrews N.C., Erdjument-Bromage M.B., Tempst P., Orkin S.H. Erythroid transcription factor NF-E2 is a haemopoietic-specific basic zipperprotein. Nature. 362:1993;722-728.
3. Baxter G.T., Kuo R.C., Jupp O.J., Vandenabeele P., MacEwan D.J. Tumor necrosis factor-alpha mediates both apoptotic cell death and cell proliferation in a human hematopoietic cell line dependent on mitotic activity and receptor subtype expression. J. Biol. Chem. 274:1999;9539-9547.
4. Bean T.L., Ney P.A. Multiple regions of p45 NF-E2 are required for beta-globin gene expression in erythroid cells. Nucleic Acids Res. 25:1997;2509-2515.
5. Beug H., Bauer A., Dolznig H., von Lindern M., Lobmayer L., Mellitzer G., Steinlein P., Wessely O., Müllner E. Avian erythropoiesis and erythroleukemia: towards understanding the role of the biomolecules involved. Biochim. Biophys. Acta. 1288:1996;35-47.
6. Bogdan C., Ding A. Taxol a microtubule-stabilizing antineoplastic agent, induces expression of TNF α and IL-1 in macrophages. J. Leukocyte Biol. 52:1992;119-121.
7. Cassidy P.B., Moos P.J., Kelly R.C., Fiztpatrick F.A. Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin. Cancer Res. 8:2002;846-855.
8. Deldar A., Stevens C.E. Development and application of in vitro models of hematopoiesis to drug development. Toxicol. Pathol. 21:1993;231-240.
9. Diaz J.F., Strobe R., Engelborghs Y., Souto A.A., Andreu J.M. Molecular recognition of taxol by microtubules. Kinetics and thermodynamics of binding of fluorescent taxol derivatives to an exposed site. J. Biol. Chem. 275:2000;26265-26276.
10. Gilmore M.M., Bishop T.R. The role of c-myb during the maturation of murine CFU-E. Blood Cells Mol. Diseases. 28:1999;68-77.
11. Golay J., Basilico L., Laffarelli L., Songia S., Broccoli V., Introna M. Regulation of hematopoietic cell proliferation and differentiation by the myb oncogene family of transcription factors. Int. J. Clin. Lab. Res. 26:1996;24-32.
12. L expression. Blood. 94:1999;87-96.
13. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J. Natl. Cancer Inst. 91:1991;1616-1634.
14. Haldar S., Basu A., Croce C.M. Bcl2 is the guardian of microtubule integrity. Cancer Res. 57:1997;229-233.
15. Hoagland H.C., Gastineau D.A. Hematological complications of cancer chemotherapy. Perry M.C. The Chemotherapy Source Book. 1996;559-569 Williams & Wilkins, Baltimore.
16. Huang Y., Fan W. IKappa B kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines. Mol. Pharmacol. 61:2002;105-113.
17. Furmanski P., Johnson C.S. Macrophage control of normal and leukemic erythropoiesis: identification of the macrophage derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor. Blood. 75:1990;2328-2384.
18. Janowska-Wieczorek A., Majka M., Ratajczak J., Ratajczak M.Z. Autocrine/paracrine mechanisms in human Hematopoiesis. Stem Cells. 19:2001;99-107.
19. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J. Interferon Cytokine Res. 18:1998;555-559.
20. Josefsen D., Mykiebust J.H., Lomo J., Sioud M., Blomhoff H.K., Smeland E.B. Differential expression of Bcl-2 homologs in human CD34+ hematopoietic progenitor cells induced to differentiate into erythroid or granulocytic cells. Stem Cells. 18:2000;261-272.
21. Juaristi J.A., Aguirre M.V., Carmuega R.J., Romero-Benitez M., Alvarez M.A., Brandan N.C. Hematotoxicity induced by paclitaxel: in vitro and in vivo assays during normal murine hematopoietic recovery. Methods Find. Exp. Pharmacol. 23:2001;161-167.
22. Kapur R., Zhang L. A novel mechanism of cooperation between c-kit and erythropoietin receptor. J. Biol. Chem. 276:2001;1099-1106.
23. Kel A.E., Kolchanov O.V., Kel A.G., Romashchenko E.A., Ananko E.V., Ignatieva T.I., Merkulova O.A. TRRD: database on transcription regulatory regions of eukaryotic genes. Mol. Biol. (Mosk.). 31:1997;521-530.
24. Koury M.J., Boundurant M.C. Erythropoietin retards DNA breakdown and prevent programmed cell death in erythroid cells. Science. 248:1990;378-381.
25. Lanni J., Lowe S., Licitra E., Liu J., Jacks T. p53 Independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. U.S.A. 94:1997;9679-9683.
26. Lieu C.H., Liu C.C., Yu T.H., Chen K.D., Chang Y.N., Lai Y.K. Role of mitogen-activated protein kinase in taxol-induced apoptosis in human leukemic U937 cells. Cell Growth Differ. 9:1998;767-776.
27. Lin C.S., Lim S.K., Agati V., Constantini F. Differential effects of an erythropoietin receptor gene disruption in primitive and definitive erythropoiesis. Genes Dev. 10:1996;154-164.
28. Majka M., Janowska-Wieczorek A., Ratajczak J., Ehrenman K., Pietrzkowski Z., Kowalska M.A., Gerwitz A.L., Emerson S.G., Ratajczak M.Z. Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood. 97:2001;3075-3085.
29. Means R.T., Krantz S.B. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 80:1992;1639-1647.
30. Metcalf D. Lineage commitment and maturation in hematopoietic cells: the case for extrinsic regulation. Blood. 92:1998;345-352.
31. Moos P.J., Fitzpatrick F.A. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 95:1998;3896-3901.
32. Moos P.J., Fitzpatrick F.A. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Differ. 8:1998;687-697.
33. L prevents antiapoptotic cell death of both primitive and definitive erythrocytes at the end of maturation. J. Exp. Med. 189:1999;1691-1698.
34. Ogawa M. Differentiation and proliferation of hemopoietic stem cells. Blood. 81:1993;2844-2853.
35. Perry M.C. Toxicity: ten years later. Semin. Oncol. 19:1992;453-457.
36. Perry Ch., Soreq H. Transcriptional regulation of erythropoiesis. Review article Eur. J. Biochem. 269:2002;3607-3618.
37. Persons D.L., Yazlovitskaya E.M., Pelling J.C. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J. Biol. Chem. 275:2000;35778-35785.
38. Rowinsky E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 48:1997;353-374.
39. Sato T., Maekawa T., Sumiko W., Kohichiro T., Nakahata T. Erythroid progenitors differentiate and mature in response to endogenous erythropoietin. J. Clin. Invest. 106:2000;263-270.
40. Schiff P., Faut J., Horowitz S. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
41. Shen S.C., Huang T.S., Jee S.H., Kuo M.L. Taxol-induced p34cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells. Cell Growth Differ. 9:1998;23-29.
42. Shivdasani R.A., Orkin S.H. Erythropoiesis and globin gene expression in mice lacking the transcription factor NF-E2. Proc. Natl. Acad. Sci. U.S.A. 92:1995;8690-8694.
43. Shivdasani R.A., Rosenblatt M.F., Zucker-Franklin D., Jackson C.W., Hunt P., Saris C.J., Orkin S.H. Transcription factor NF-E2 is required for plateled formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 81:1995;695-704.
44. Shtil A.A., Mandlekar S., Yu R., Walter R.J., Hagen K., Tan T.H., Roninson I.B., Kong A.N. Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene. 18:1999;377-384.
45. L through STAT 5 in Erythropoietin-dependent progenitors cell lines. J. Biol. Chem. 274:1999;22165-22169.
46. Subbaramaiah K., Hart J.C., Norton L., Dannenberg A.J. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J. Biol. Chem. 275:2000;14838-14845.
47. Toki T., Arai K., Terui K., Komatsu N., Yokohama M., Katsuoka F., Yamamoto M., Ito E. Functional characterization of the two alternative promoters of human p45 NF-E2 gene. Exp. Hematol. 10:2000;1113-1119.
48. Torres K., Horowitz S.B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res. 58:1998;3620-3626.
49. Udupa K.B., Sharma B.G. Possible rol of tumor necrosis factor-alpha in erythropoietic suppression by endotoxin and granulocyte/macrophage colony stimulating factor. Am. J. Hematol. 52:1996;178-183.
50. Von Hoff D.D. The taxoids: same roots, different drugs. Semin. Oncol. 24:1997;3-10.
51. Wang T.H., Popp D.M., Wang H.S., Saitoh M., Mural J.G., Henley D.C., Ichijo H., Wimalasena J. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J. Biol. Chem. 274:1999;8208-8216.
52. Weiss M.J., Orkin S.H. Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis. Proc. Natl. Acad. Sci. U.S.A. 92:1995;9623-9627.
53. White J.R., Weston K. Myb is required for self-renewal in a model system of early hematopoiesis. Oncogene. 19:2000;1196-1205.
54. Wood P.A., Hrushesky W.J. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J. Clin. Invest. 95:1995;1650-1659.
55. Zhang Z., Liu Q., Lantry L.E., Wang Y., Kelloff G.J., Anderson M.W., Wiseman R.W., Lubet R.A., You M. A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res. 60:2000;901-907.
56. Zon L.I., Youssoufian H., Mather C., Lodish H.F., Orkin S.H. Activation of the erythropoietin receptor promoter by transcription factor GATA-1. Proc. Natl. Acad. Sci. U.S.A. 88:1991;10638-10641.